We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App




LGC Clinical Diagnostics Acquires Urinalysis Quality Controls Provider Kova International

By LabMedica International staff writers
Posted on 25 Jul 2023
Print article
Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)
Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)

LGC Clinical Diagnostics (Middlesex, UK), a business unit of LGC and a leading provider of biological materials and viral antigens, has acquired Kova International, Inc. (Garden Grove, CA, USA), a developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories. Kova has two manufacturing facilities, one focusing on urinalysis quality controls and the other on toxicology quality controls. Both the manufacturing facilities are certified to ISO 13485:2016 quality management system standards and guidelines, as well as cGMP qualified to manufacture quality control products, and are registered FDA manufacturing sites for the clinical diagnostic laboratory industry.

Kova’s quality control products are employed in hospitals, employee wellness programs, forensic testing and medical device manufacturers production and Quality Assurance (QA) programs. The acquisition expands LGC Clinical Diagnostics’ clinical quality control portfolio, complementing its wide range of offerings across biochemistry, serology, molecular, and clinical genomics quality controls and reference materials. LGC Clinical Diagnostics has over 35 years of industry experience and caters to more than 20,000 customers in over 100 counties. The company is keen on combining Kova’s expertise with its own in order to offer its customers unmatched solutions with expanded capabilities.

“We are excited to bring Kova’s established clinical urinalysis and toxicology quality controls into LGC Clinical Diagnostics,” said Bharathi Anekella, Executive Vice President & General Manager of LGC Clinical Diagnostics. “Kova and LGC Clinical Diagnostics are an excellent fit. Our focus on delivering confidence to clinical laboratories in test precision, accuracy, and conformance to international standards, perfectly aligns us with a common objective of Science for a Safer World.”

Related Links:
LGC
Kova International, Inc.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Coagulation Analyzer
CS-2400

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.